Total Payments
$3,477
2024 Payments
$1,222
Companies
30
Transactions
106
Medicare Patients
6,439
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$2,352 (67.6%)
Consulting$1,125 (32.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,352 | 103 | 67.6% |
| Consulting Fee | $1,125 | 3 | 32.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $962.30 | 4 | $0 (2024) |
| Lilly USA, LLC | $326.08 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $272.46 | 16 | $0 (2018) |
| GE HealthCare | $217.06 | 3 | $0 (2022) |
| Foundation Medicine, Inc. | $204.27 | 1 | $0 (2018) |
| SOBI, INC | $200.00 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $168.59 | 12 | $0 (2018) |
| PFIZER INC. | $120.72 | 15 | $0 (2018) |
| AbbVie, Inc. | $105.24 | 1 | $0 (2018) |
| Incyte Corporation | $91.46 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,222 | 4 | AstraZeneca Pharmaceuticals LP ($925.00) |
| 2023 | $110.26 | 1 | Lilly USA, LLC ($110.26) |
| 2022 | $320.95 | 4 | GE HealthCare ($217.06) |
| 2020 | $91.46 | 1 | Incyte Corporation ($91.46) |
| 2018 | $516.09 | 15 | Foundation Medicine, Inc. ($204.27) |
| 2017 | $1,216 | 81 | Novartis Pharmaceuticals Corporation ($221.64) |
All Payment Transactions
106 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 09/07/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $96.68 | General |
| Category: Oncology | ||||||
| 08/07/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Oncology | ||||||
| 05/13/2023 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $110.26 | General |
| Category: Oncology | ||||||
| 11/19/2022 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $103.89 | General |
| Category: Oncology | ||||||
| 05/18/2022 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $76.61 | General |
| 05/18/2022 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $76.61 | General |
| 01/29/2022 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $63.84 | General |
| 02/14/2020 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $91.46 | General |
| Category: Hematology/Oncology | ||||||
| 11/15/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $105.24 | General |
| Category: Virology | ||||||
| 02/28/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.39 | General |
| 02/27/2018 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: BioOncology | ||||||
| 02/22/2018 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $12.34 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 02/21/2018 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: Hematology / Oncology | ||||||
| 02/01/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.08 | General |
| Category: Oncology | ||||||
| 01/26/2018 | Novartis Pharmaceuticals Corporation | VOTRIENT (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: ONCOLOGY | ||||||
| 01/25/2018 | Purdue Pharma L.P. | OXYCONTIN (Drug) | Food and Beverage | Cash or cash equivalent | $13.51 | General |
| Category: PAIN MANAGEMENT | ||||||
| 01/24/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Oncology | ||||||
| 01/18/2018 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONFOCUS, FOUNDATIONACT | Food and Beverage | In-kind items and services | $204.27 | General |
| Category: ONCOLOGY | ||||||
| 01/17/2018 | Lexicon Pharmaceuticals, Inc. | Xermelo (Drug) | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: Carcinoid Syndrome Diarrhea | ||||||
| 01/11/2018 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: HEMATOLOGY | ||||||
| 01/11/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Oncology | ||||||
| 01/05/2018 | Novartis Pharmaceuticals Corporation | VOTRIENT (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2018 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 1,725 | 40,545 | $1.9M | $574,531 |
| 2022 | 55 | 1,917 | 26,495 | $1.9M | $543,277 |
| 2021 | 45 | 1,619 | 16,582 | $1.1M | $361,860 |
| 2020 | 33 | 1,178 | 8,162 | $338,409 | $90,592 |
Total Patients
6,439
Total Services
91,784
Medicare Billing
$1.6M
Procedure Codes
186
All Medicare Procedures & Services
186 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 18 | 7,000 | $792,750 | $267,720 | 33.8% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 3,960 | $389,070 | $128,656 | 33.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 127 | 281 | $121,181 | $35,234 | 29.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 1,800 | $87,300 | $32,908 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 123 | 219 | $67,598 | $20,390 | 30.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 89 | 175 | $75,338 | $17,568 | 23.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 21 | 63 | $47,439 | $7,875 | 16.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $24,413 | $6,628 | 27.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 18 | 22 | $20,911 | $5,222 | 25.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 27 | 84 | $20,265 | $4,764 | 23.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 50 | $14,175 | $4,515 | 31.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 122 | 405 | $9,011 | $4,006 | 44.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 142 | 512 | $7,330 | $3,973 | 54.2% |
| J9025 | Injection, azacitidine, 1 mg | Office | 2023 | 11 | 10,695 | $37,433 | $3,738 | 10.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 133 | 507 | $8,873 | $3,701 | 41.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 57 | 147 | $13,708 | $3,351 | 24.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 13 | 8,160 | $32,640 | $3,218 | 9.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 40 | 59 | $12,803 | $2,802 | 21.9% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 32 | 279 | $5,859 | $2,543 | 43.4% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 19 | 24 | $13,752 | $2,255 | 16.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 26 | 42 | $8,747 | $2,080 | 23.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 47 | $4,277 | $1,020 | 23.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 26 | 40 | $3,540 | $985.14 | 27.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 40 | 70 | $4,323 | $758.26 | 17.5% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 21 | 46 | $2,990 | $722.87 | 24.2% |
About Dr. Meng Zhao, M.D
Dr. Meng Zhao, M.D is a Internal Medicine healthcare provider based in Everett, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/14/2009. The National Provider Identifier (NPI) number assigned to this provider is 1083848337.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Meng Zhao, M.D has received a total of $3,477 in payments from pharmaceutical and medical device companies, with $1,222 received in 2024. These payments were reported across 106 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($2,352).
As a Medicare-enrolled provider, Zhao has provided services to 6,439 Medicare beneficiaries, totaling 91,784 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 186 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Everett, WA
- Active Since 05/14/2009
- Last Updated 07/31/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1083848337
Products in Payments
- CALQUENCE (Drug) $525.00
- IMFINZI (Biological) $400.00
- VERZENIO (Drug) $310.83
- FOUNDATIONONE (Device) $204.27
- VONJO (Drug) $200.00
- OPDIVO (Biological) $143.94
- Venclexta (Drug) $105.24
- JAKAFI (Drug) $91.46
- PROVENGE (Drug) $89.62
- IBRANCE (Drug) $73.68
- JADENU (Drug) $73.08
- TASIGNA (Drug) $68.79
- TECENTRIQ (Biological) $56.74
- KEYTRUDA (Biological) $48.53
- Imbruvica (Drug) $48.43
- ADCETRIS (Biological) $46.74
- AFINITOR (Drug) $43.19
- Abraxane (Drug) $42.41
- IMFINZI (Drug) $37.30
- MEKINIST (Drug) $36.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Everett
Dr. Conrad Jablonski, Md, MD
Internal Medicine — Payments: $53,897
Internal Medicine $53,897
Ricardo Cardona Guarache, M.d, M.D
Internal Medicine — Payments: $25,669
Internal Medicine $25,669
Deepak Thatai, Md, MD
Internal Medicine — Payments: $18,399
Internal Medicine $18,399
Yoshio Inoue, M.d, M.D
Internal Medicine — Payments: $7,155
Internal Medicine $7,155
Dr. Irina Milman, Md, MD
Internal Medicine — Payments: $6,747
Internal Medicine $6,747
Dr. James Liadis, M.d, M.D
Internal Medicine — Payments: $3,449
Internal Medicine $3,449